[1]
|
UNAIDS (Joint United Nations Programme on HIV/AIDS) (2020) 2020 Global Aids Update—Seizing the Mo-ment—Tackling Entrenched Inequalities to End Epidemics. Joint United Nations Programme on HIV/AIDS, Geneva.
https://www.unaids.org/en/resources/documents/2020/globalaids-report
|
[2]
|
Viard, J.P. (2014) Comorbidities in HIV Infection and Aging with HIV. La Revue du Praticien, 64, 1086-1090.
|
[3]
|
中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版) [J]. 协和医学杂志, 2022, 13(2): 203-226.
|
[4]
|
Raposo, M.A., de Almeida Armiliato, G.N., Guimarães, N.S., et al. (2017) Metabolic Disorders and Car-diovascular Risk in People Living with HIV/AIDS without the Use of Antiretroviral Therapy. Revista da Sociedade Bra-sileira de Medicina Tropical, 50, 598-606. https://doi.org/10.1590/0037-8682-0258-2017
|
[5]
|
Dai, L., Liu, A., Zhang, H., et al. (2019) Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Current HIV research, 17, 324-334. https://doi.org/10.2174/1570162X17666191025115508
|
[6]
|
石峰, 刘敏, 李明俊, 刘倩, 吴玉珊, 何坤. 含克力芝的抗逆转录病毒治疗方案对不同性别、不同年龄HIV感染人群血脂水平的影响研究[J]. 中国实用医药, 2021, 16(28): 155-158.
|
[7]
|
余旻虹, 赵艳伟, 杨慧, 宋晓璟, 何叶, 李佳倩, 等. 306例艾滋病患者的血脂异常情况及相关因素分析[J]. 中华实验和临床病毒学杂志, 2020(2): 122-127.
|
[8]
|
Mizushima, D., Dung, N.T.H., Dung, N.T., Matsumoto, S., Tanuma, J., et al. (2020) Dyslipidemia and Cardiovascular Disease in Vietnamese People with HIV on Antiretroviral Therapy. Global Health & Medicine, 2, 39-42.
https://doi.org/10.35772/ghm.2019.01035
|
[9]
|
Kauppinen, K.J., Kivelä, P. and Sutinen, J. (2019) Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. AIDS Patient Care and STDs, 33, 500-506.
https://doi.org/10.1089/apc.2019.0236
|
[10]
|
Sun, L.-Q., Liu, J.-Y., He, Y., Zhou, Y., Xu, L.M., Zhang, L.K., et al. (2020) Evolution of Blood Lipids and Risk Factors of Dyslipidemia among People Living with Human Immunodefi-ciency Virus who Had Received First-Line Antiretroviral Regimens for 3 Years in Shenzhen. Chinese Medical Journal, 133, 2808-2815.
https://doi.org/10.1097/CM9.0000000000001245
|
[11]
|
Muche Belete, A., Seifu, D., Menon, M., Amogne, W., Shewa, A. and Adela Tefera, A (2021) Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia. HIV/AIDS - Research and Palliative Care, 13, 217-227. https://doi.org/10.2147/HIV.S296170
|
[12]
|
Liu, D., Zhang, X., Kang, J., Gao, F., He, Y. and He, S. (2021) Gradual Increasing Dyslipidemia in Treatment-Naive Male Patients with Human Immunodeficiency Virus and Treated with Tenofovir plus Lamivudine plus Efavirenz for 3 Years. Diabetology & Metabolic Syndrome, 13, Article No. 135. https://doi.org/10.1186/s13098-021-00756-y
|
[13]
|
Tre-villyan, J.M., Wong, G., Puls, R., Petoumenos, K., Emery, S., Mellett, N.A., et al. (2018) Changes in Plasma Lipidome Following Initiation of Antiretroviral Therapy. PLOS ONE, 13, Article ID: e0202944.
https://doi.org/10.1371/journal.pone.0202944
|
[14]
|
Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., et al. (2018) Improvement of Lipid Profile after Switching from Efavirenz or Ritonavir-Boosted Prote-ase Inhibitors to Rilpivirine or Once-Daily Integrase Inhibitors: Results from a Large Observational Cohort Study (SCOLTA). BMC Infectious Diseases, 18, Article No. 357. https://doi.org/10.1186/s12879-018-3268-5
|
[15]
|
The RESPOND Study Group (2021) Incidence of Dyslipidemia in People with HIV Who Are Treated with Integrase Inhibi-tors versus Other Antiretroviral Agents. AIDS, 35, 869-882. https://doi.org/10.1097/QAD.0000000000002811
|
[16]
|
Tadesse, B.T., Foster, B.A., Chala, A., Chaka, T.E., Bi-zuayehu, T., Ayalew, F., et al. (2019) HIV and cART-Associated Dyslipidemia among HIV-Infected Children. Journal of Clinical Medicine, 8, Article No. 430.
https://doi.org/10.3390/jcm8040430
|
[17]
|
Santiprabhob, J., Tanchaweng, S., Maturapat, S., Maleesatharn, A., Ler-mankul, W., Sricharoenchai, S., et al. (2017) Metabolic Disorders in HIV-Infected Adolescents Receiving Protease In-hibitors. BioMed Research International, 2017, Article ID: 7481597. https://doi.org/10.1155/2017/7481597
|
[18]
|
马春涛, 王强, 张煜昆, 孟宪宇. 2009-2019年我国艾滋病免费抗病毒治疗药品构成分析[J]. 中国医药导报, 2021, 18(17): 157-160+168+封4.
|
[19]
|
Nansseu, J.R., Bigna, J.J., Kaze, A.D. and Noubiap, J.J. (2018) Incidence and Risk Factors for Prediabetes and Diabetes Mellitus among HIV-Infected Adults on Antiretroviral Therapy: A Systematic Re-view and Meta-analysis. Epidemiology, 29, 431-441. https://doi.org/10.1097/EDE.0000000000000815
|
[20]
|
Kumar, S. and Samaras, K. (2018) The Impact of Weight Gain during HIV Treatment on Risk of Pre-Diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Frontiers in Endocrinology, 9, Article No. 705.
https://doi.org/10.3389/fendo.2018.00705
|
[21]
|
Nolan, N.S., Adamson, S., Reeds, D. and O’Halloran, J.A. (2021) Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus. Open Forum Infectious Diseases, 8, ofab077.
https://doi.org/10.1093/ofid/ofab077
|
[22]
|
Paengsai, N., Jourdain, G., Salvadori, N., Tantraworasin, A., Mary, J.Y., Cressey, T.R., et al. (2019) Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings. Open Forum Infectious Diseases, 6, ofz298. https://doi.org/10.1093/ofid/ofz298
|
[23]
|
Echecopar-Sabogal, J., D’Angelo-Piaggio, L., Chanamé-Baca, D.M. and Ugarte-Gil, C. (2018) Association between the Use of Protease Inhibitors in Highly Active Antiretroviral Therapy and Incidence of Diabetes Mellitus and/or Metabolic Syndrome in HIV-Infected Patients: A Systematic Review and Me-ta-Analysis. International Journal of STD & AIDS, 29, 443-452. https://doi.org/10.1177/0956462417732226
|
[24]
|
Tadesse, W.T., Adankie, B.T., Shibeshi, W., Amogne, W., Aklillu, E. and Engidawork, E (2022) Prevalence and Predictors of Glucose Metabolism Disorders among People Living with HIV on Combination Antiretroviral Therapy. PLOS ONE, 17, e0262604. https://doi.org/10.1371/journal.pone.0262604
|
[25]
|
Rebeiro, P.F., Jenkins, C.A., Bian, A., Lake, J.E., Bourgi, K., Moore, R.D., et al. (2021) Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships with Integrase In-hibitor-Based Initial Antiretroviral Therapy among Persons with Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases, 73, e2234-e2242.
https://doi.org/10.1093/cid/ciaa1403
https://pubmed.ncbi.nlm.nih.gov/32936919
|
[26]
|
Shah, S., Hindley, L. and Hill, A. (2021) Are New Antiretroviral Treatments Increasing the Risk of Weight Gain? Drugs, 81, 299-315. https://doi.org/10.1007/s40265-020-01457-y
|
[27]
|
Shah, S. and Hill, A. (2021) Risks of Metabolic Syndrome and Diabetes with Integrase Inhibitor-Based Therapy. Current Opinion in Infectious Diseases, 34, 16-24. https://doi.org/10.1097/QCO.0000000000000695
|
[28]
|
Bourgi, K., Jenkins, C.A., Rebeiro, P.F., Shepherd, B.E., Palella, F., Moore, R.D., et al. (2020) Weight Gain among Treatment-Naïve Persons with HIV Starting Integrase Inhibi-tors Compared to Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors in a Large Observational Co-hort in the United States and Canada. Journal of the International AIDS Society, 23, Article ID: e25484. https://doi.org/10.1002/jia2.25484
|
[29]
|
Tiozzo, E., Rodriguez, A., Konefal, J., Farkas, G.J., Maher, J.L. and Lewis, J.E. (2021) The Relationship between HIV Duration, Insulin Resistance and Diabetes Risk. International Journal of En-vironmental Research and Public Health, 18, Article No. 3926. https://doi.org/10.3390/ijerph18083926
|
[30]
|
Duguma, F., Gebisa, W., Mamo, A., Tamiru, D. and Woyesa, S. (2020) Diabetes Mellitus and Associated Factors among Adult HIV Patients on Highly Active Anti-Retroviral Treatment. HIV/AIDS - Research and Palliative Care, 12, 657-665. https://doi.org/10.2147/HIV.S279732
|
[31]
|
Han, W.M., Jiamsakul, A., Kiertiburanakul, S., Ng, O.T., Sim, B., Sun, L.P., et al. (2019) Diabetes Mellitus Burden among People Living with HIV from the Asia-Pacific Region. Journal of the International AIDS Society, 22, Article ID: e25236. https://doi.org/10.1002/jia2.25236
|
[32]
|
McMahon, C.N., Petoumenos, K., Hesse, K., Carr, A., Cooper, D.A. and Samaras, K. (2018) High Rates of Incident Diabetes and Prediabetes Are Evident in Men with Treated HIV Followed for 11 Years. AIDS, 32, 451-459.
https://doi.org/10.1097/QAD.0000000000001709
|
[33]
|
何小清, 沈银忠, 张仁芳, 刘莉, 王江蓉, 陈军. 未启动抗反转录病毒治疗的人类免疫缺陷病毒/艾滋病患者发生心血管疾病的风险评估[J]. 中华传染病杂志, 2020, 38(10): 640-645.
|
[34]
|
Ballocca, F., D’Ascenzo, F., Gili, S., Grosso Marra, W. and Gaita, F. (2017) Cardiovascular Disease in Patients with HIV. Trends in Cardiovascular Medicine, 27, 558-563. https://doi.org/10.1016/j.tcm.2017.06.005
|
[35]
|
Shah A S V, Stelzle, D., Lee, K.K., Beck, E.J., Alam, S., Clifford, S., et al. (2018) Global Burden of Atherosclerotic Cardiovascular Disease in People Living with HIV: Systematic Review and Meta-Analysis. Circulation, 138, 1100-1112.
https://doi.org/10.1161/CIRCULATIONAHA.117.033369
|
[36]
|
Guo, F., Hsieh, E., Lyu, W., Han, Y., Xie, J., Li, Y., et al. (2017) Cardiovascular Disease Risk among Chinese Antiretroviral-Naïve Adults with Advanced HIV Disease. BMC Infectious Diseases, 17, Article No. 287.
https://doi.org/10.1186/s12879-017-2358-0
|
[37]
|
Pierre, S., Seo, G., Rivera, V.R., Walsh, K.F., Victor, J.J., Charles, B., et al. (2019) Prevalence of Hypertension and Cardiovascular Risk Factors among Long-Term AIDS Survi-vors: A Report from the Field. The Journal of Clinical Hypertension, 21, 1558-1566. https://doi.org/10.1111/jch.13663
|
[38]
|
Ryom, L., Lundgren, J.D., El-Sadr, W., Reiss, P., Kirk, O., Law, M., et al. (2018) Cardiovascular Disease and Use of Contemporary Protease Inhibitors: The D:A:D International Prospective Mul-ticohort Study. The Lancet. HIV, 5, e291-e300. https://doi.org/10.1016/S2352-3018(18)30043-2
|
[39]
|
Losina, E., Hyle, E.P., Borre, E.D., Linas, B.P., Sax, P.E., Weinstein, M.C., et al. (2017) Projecting 10-Year, 20-Year, and Lifetime Risks of Cardiovascular Disease in Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 65, 1266-1271. https://doi.org/10.1093/cid/cix547
|
[40]
|
Maggi, P., Di Biagio, A., Rusconi, S., Cicalini, S., d’Abbraccio, M., d’Ettorre, G., et al. (2017) Cardiovascular Risk and Dyslipidemia among Persons Living with HIV: A Review. BMC Infectious Diseases, 17, Article No. 551.
https://doi.org/10.1186/s12879-017-2626-z
|